Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Pyxis Oncology Inc (PYXS)

Pyxis Oncology Inc (PYXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Wall street sign in New York City with American flags and New York Stock Exchange in background by kasto80 via iStock
Stocks Rise Before the Open With U.S. Economic Data in Focus, Nvidia Slips on Disappointing Forecast Barchart - Thu Nov 21, 4:41AM CST

December S&P 500 E-Mini futures (ESZ24) are up +0.20%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.09% this morning as investors looked ahead to a raft of U.S. economic data that could provide...

TGT : 125.01 (+2.81%)
EVTC : 36.31 (+0.69%)
NVDA : 141.95 (-3.22%)
DE : 446.65 (+2.08%)
PYXS : 1.9000 (-9.52%)
INTU : 640.12 (-5.68%)
SNOW : 167.44 (-2.28%)
JD-.LN : 93.460 (-2.07%)
NQZ24 : 20,849.75s (+0.10%)
FN : 230.43 (+0.18%)
CPRT : 62.70 (+10.19%)
QCOM : 156.79 (+0.86%)
Pyxis Oncology Reports Promising Phase 1 Clinical Data for PYX-201 in Multiple Solid Tumors and Announces Collaboration with Merck to Evaluate Combination Therapy Quiver Quantitative, Inc. - Thu Nov 21, 1:20AM CST

PYX-201 shows promising efficacy and safety in solid tumors, with expansion trials set to begin in 2025.Quiver AI SummaryPyxis Oncology announced positive preliminary results from a Phase 1 dose escalation...

PYXS : 1.9000 (-9.52%)
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data GlobeNewswire - Wed Nov 20, 3:05PM CST

PYXS : 1.9000 (-9.52%)
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024 GlobeNewswire - Tue Nov 12, 6:30AM CST

PYXS : 1.9000 (-9.52%)
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201 GlobeNewswire - Mon Nov 11, 6:00AM CST

PYXS : 1.9000 (-9.52%)
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review FinancialNewsMedia - Fri Oct 13, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END

ONCY : 0.9541 (-2.64%)
ONC.TO : 1.33 (-2.92%)
PYXS : 1.9000 (-9.52%)
AZN : 65.63 (+2.13%)
LLY : 748.01 (-0.25%)
MRUS : 45.49 (+2.56%)
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review PR Newswire - Fri Oct 13, 2023

/PRNewswire/ -- USA News Group - Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy...

ONC.TO : 1.33 (-2.92%)
ONCY : 0.9541 (-2.64%)
PYXS : 1.9000 (-9.52%)
AZN : 65.63 (+2.13%)
LLY : 748.01 (-0.25%)
MRUS : 45.49 (+2.56%)
Breakthroughs in Pancreatic Cancer Treatment: How FDA Designations are Changing the Game BayStreet.ca - Wed Oct 11, 2023

USA News Group – Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the...

ONCY : 0.9541 (-2.64%)
ONC.TO : 1.33 (-2.92%)
PYXS : 1.9000 (-9.52%)
AZN : 65.63 (+2.13%)
LLY : 748.01 (-0.25%)
MRUS : 45.49 (+2.56%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ: PYXS) PR Newswire - Thu Sep 21, 2023

/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ: PYXS) concerning possible breaches of...

PYXS : 1.9000 (-9.52%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ: PYXS) PR Newswire - Thu Jun 15, 2023

/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ: PYXS) concerning possible breaches of...

PYXS : 1.9000 (-9.52%)

Barchart Exclusives

How to Invest for Kids: Understanding the Basics Barchart - Sat Nov 23, 1:30PM CST
A good way to show kids the value of compounding money is to ask if they’d rather have a $100 bill today or a penny that doubles every day for 30 days. They will be surprised to hear that in 30 days, that penny would be worth about $5.4 million dollars! Here's a guide to the types of accounts you can open for your children or grandchildren. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot